Utilization and Outcomes of Pharmacologic Migraine Prophylaxis: A Multicenter Cross-Sectional Study at TASH, Yekatit 12, and Zewditu Hospitals, Addis Ababa, Ethiopia.

dc.contributor.advisorYared Mamushet
dc.contributor.advisorMichael Tesfaye
dc.contributor.advisorSelam Kifelew
dc.contributor.authorAlembante Mulye
dc.date.accessioned2026-06-22T15:28:52Z
dc.date.available2026-06-22T15:28:52Z
dc.date.issued2025-02-10
dc.description.abstractBackground: Migraine is a common and disabling neurological disorder that significantlyimpacts an individual’s quality of life. Globally, headache disorders rank third among causes ofdisability, with migraine being a leading contributor. In Ethiopia, migraine accounts for 17.7% ofheadache disorders, yet remains underdiagnosed and undertreated. While international studieshave highlighted gaps in migraine prophylaxis, there is limited data on its utilization andeffectiveness in Ethiopia. This study aims to assess the use of pharmacologic migraineprophylaxis and evaluate patient outcomes at specialized centers in Addis Ababa. Methods: The study included migraine patients aged 18 years and older who were receivingregular follow-up care in neurology outpatient departments. Data were collected from patientrecords and follow-up visits between August 2024 and January 2025. A total of 90 patients wereincluded in the analysis, after accounting for incomplete records and non-respondents. Keymigraine-related variables, including attack frequency, pain severity, episode duration, andemergency room visits, were collected using structured questionnaires administered throughthe KoboToolbox platform. Data collection involved both in-person and phone interviews withpatients. Descriptive statistics were used to analyze the data, with a p-value of <0.05considered statistically significant. Result: Among the 90 participants, 80% reported being prescribed migraine prophylacticmedications. Of those on prophylaxis, 66.7% experienced improvements in frequency, severity,and duration of migraine attacks. Regarding treatment effectiveness, 45.8% found theprophylactic therapy very effective, 38.8% rated it moderately effective, and 15.2% found itineffective. Treatment adherence was reported as good in 66.7% of patients, with 72.2%continuing their prescribed therapy Conclusion:This study demonstrates a high utilization of pharmacologic preventive therapy(80%) among migraine patients at three specialized hospitals in Addis Ababa, significantlyhigher than the 3-13% and 12.4% reported in international studies. Preventive therapyeffectively reduced migraine frequency, duration, and severity
dc.identifier.urihttps://etd.aau.edu.et/handle/123456789/8361
dc.language.isoen
dc.publisherAddis Ababa University
dc.subjectUtilization and outcomes pharmacologic migraine A multicenter cross-sectional
dc.titleUtilization and Outcomes of Pharmacologic Migraine Prophylaxis: A Multicenter Cross-Sectional Study at TASH, Yekatit 12, and Zewditu Hospitals, Addis Ababa, Ethiopia.
dc.typeThesis

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Alembante_ Mulye_2025_ETD.pdf
Size:
870.65 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: